KeyCorp Downgrades Evolent Health (NYSE:EVH) to Sector Weight

Evolent Health (NYSE:EVH) was downgraded by analysts at KeyCorp from an “overweight” rating to a “sector weight” rating in a research note issued to investors on Wednesday, MarketBeat reports.

Several other brokerages also recently weighed in on EVH. Stephens upgraded shares of Evolent Health from an “equal weight” rating to an “overweight” rating and set a $7.00 price objective for the company in a research report on Thursday, November 13th. Oppenheimer reduced their price target on shares of Evolent Health from $18.00 to $12.00 and set an “outperform” rating for the company in a research report on Wednesday, November 12th. Citizens Jmp decreased their price objective on shares of Evolent Health from $11.00 to $10.00 and set a “market outperform” rating for the company in a research note on Tuesday, January 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolent Health in a research report on Monday, December 29th. Finally, Citigroup reduced their target price on Evolent Health from $9.50 to $6.00 and set a “buy” rating for the company in a report on Friday, January 9th. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $9.33.

Evolent Health Trading Down 7.8%

NYSE:EVH opened at $2.56 on Wednesday. Evolent Health has a 1 year low of $2.52 and a 1 year high of $12.06. The stock has a market cap of $285.14 million, a P/E ratio of -1.62 and a beta of 0.27. The company has a debt-to-equity ratio of 1.25, a quick ratio of 1.33 and a current ratio of 1.33. The stock has a 50-day simple moving average of $3.54 and a 200-day simple moving average of $5.87.

Institutional Trading of Evolent Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC lifted its position in Evolent Health by 88.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock worth $29,000 after acquiring an additional 1,194 shares during the period. CIBC Private Wealth Group LLC raised its stake in shares of Evolent Health by 4,000.0% during the third quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock worth $35,000 after purchasing an additional 4,000 shares during the last quarter. Strs Ohio acquired a new stake in shares of Evolent Health during the first quarter worth $47,000. Vise Technologies Inc. acquired a new stake in shares of Evolent Health during the fourth quarter worth $50,000. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in Evolent Health in the 3rd quarter valued at $51,000.

Trending Headlines about Evolent Health

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Earnings beat consensus: Evolent reported Q4 EPS of $0.08 vs. the Zacks consensus $0.06, showing an improvement from a loss a year ago — a near-term positive for profitability expectations. Evolent Health (EVH) Q4 Earnings Top Estimates
• Positive Sentiment: Operational growth in specialty area: Management highlighted strong oncology growth and strategic progress during the Q4 earnings call, which supports longer-term revenue diversification. Evolent Health Inc (EVH) Q4 2025 Earnings Call Highlights: Strong Oncology Growth and Strategic …
• Positive Sentiment: Revenue guidance range modestly constructive: The company provided FY‑2026 revenue guidance of roughly $2.4B–$2.6B, which overlaps and tops the consensus midpoint — a sign management expects recovery/stability in revenue. Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results
• Positive Sentiment: Analyst sentiment modestly favorable: Coverage shows a consensus recommendation of “Moderate Buy,” supporting demand from some institutional investors. Evolent Health, Inc (NYSE:EVH) Receives Consensus Recommendation of “Moderate Buy” from Analysts
• Neutral Sentiment: Quarter largely in line with expectations: Several summaries describe Q4 results and revenue as roughly in line with street estimates, limiting an outsized surprise. Evolent Health (NYSE:EVH) Reports Q4 CY2025 In Line With Expectations
• Neutral Sentiment: Full disclosures available: Press release, slide deck and call transcript were posted for investors to review details and guidance assumptions. View Press Release / Slide Deck
• Negative Sentiment: Significant YoY revenue decline: Q4 revenue fell ~27.5% year-over-year to $468.7M, and the company reported a negative net margin (~‑6.2%), raising concerns about near-term top-line momentum and profitability. Evolent Health Q4 results and metrics
• Negative Sentiment: EPS guidance clarity lacking: Public commentary/filings did not provide clear FY‑2026 EPS guidance in the release, which leaves investors with uncertainty about near-term earnings trajectory. Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.